|
US4401820A
(en)
|
1981-01-23 |
1983-08-30 |
Tanabe Seiyaku Co., Ltd. |
Process for racemizing optically active α-amino acids or a salt thereof
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
DE68920693T2
(de)
|
1988-03-30 |
1995-05-24 |
Toray Industries |
Gefriergetrocknete Zusammensetzung, die ein mit Meerrettichperoxydase markiertes Fab'-Fragment eines gegen menschliches Beta-Interferon gerichteten Antikörpers und Trehalose enthält; EIA Kit, der diese Zusammensetzung enthält.
|
|
WO1989011297A1
(en)
|
1988-05-27 |
1989-11-30 |
Centocor, Inc. |
Freeze-dried formulation for antibody products
|
|
DE69332643T2
(de)
|
1992-09-16 |
2003-11-27 |
The Scripps Research Institute, La Jolla |
Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
|
|
SI1516628T1
(sl)
|
1995-07-27 |
2013-10-30 |
Genentech, Inc. |
Stabilna izotonična liofilizirana proteinska formulacija
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
ZA966075B
(en)
|
1995-07-27 |
1998-01-19 |
Genentech Inc |
Protein formulation.
|
|
WO1997010846A1
(en)
|
1995-09-18 |
1997-03-27 |
Intracel Corporation |
Neutralizing monoclonal antibodies to respiratory syncytial virus
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
MXPA01005515A
(es)
|
1998-12-01 |
2003-07-14 |
Protein Design Labs Inc |
Anticuerpos humanizados para gamma-interferon.
|
|
EP2193809B1
(en)
|
1999-02-22 |
2015-04-08 |
University of Connecticut |
Albumin-free factor VIII formulations
|
|
WO2000053631A1
(en)
|
1999-03-11 |
2000-09-14 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
|
US7090847B1
(en)
|
1999-09-09 |
2006-08-15 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
|
IL148300A0
(en)
|
1999-09-09 |
2002-09-12 |
Schering Corp |
Mammalian cytokines; related reagents and methods
|
|
JP2003527334A
(ja)
|
1999-10-22 |
2003-09-16 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Ａ３３抗原特異的免疫グロブリン産物を用いるａ３３抗原を発現する癌の影響を低減する方法
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
IL155002A0
(en)
|
2000-10-12 |
2003-10-31 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
|
JP4731793B2
(ja)
|
2000-12-28 |
2011-07-27 |
アルセア テクノロジーズ インコーポレイテッド |
抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
|
|
EP1801123A3
(en)
|
2000-12-28 |
2007-11-21 |
Altus Pharmaceuticals Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
|
WO2002102303A2
(en)
|
2001-05-01 |
2002-12-27 |
Medimmune, Inc. |
Crystals and structure of synagis fab
|
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
|
AU2002322295C1
(en)
|
2001-06-21 |
2008-12-18 |
Altus Pharmaceuticals Inc. |
Spherical protein particles and methods of making and using them
|
|
DK2270052T3
(en)
|
2001-06-26 |
2018-07-02 |
Amgen Inc |
Antibodies to OPGL
|
|
CA2454587C
(en)
|
2001-07-25 |
2012-11-13 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
IL161677A0
(en)
|
2001-11-08 |
2004-09-27 |
Protein Design Labs |
Stable liquid pharmaceutical formulation of igg antibodies
|
|
DE10207178A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Komponenten für die Herstellung amphoterer Liposomen
|
|
DK1478394T3
(da)
|
2002-02-27 |
2008-10-13 |
Immunex Corp |
Stabiliseret TNFR-Fc formulation med arginin
|
|
US20070134247A9
(en)
|
2002-04-12 |
2007-06-14 |
Ramot At Tel Aviv University Ltd. |
Prevention of brain inflammation as a result of induced autoimmune response
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
EP1537878B1
(en)
|
2002-07-03 |
2010-09-22 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
US20040091490A1
(en)
|
2002-08-28 |
2004-05-13 |
Robert Johnson |
Stable pH optimized formulation of a modified antibody
|
|
US20040121370A1
(en)
|
2002-09-11 |
2004-06-24 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
|
US20040191243A1
(en)
|
2002-12-13 |
2004-09-30 |
Bei Chen |
System and method for stabilizing antibodies with histidine
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
|
WO2004071517A2
(en)
|
2003-02-06 |
2004-08-26 |
Schering Corporation |
Uses of il-23 related reagents
|
|
RU2358763C2
(ru)
|
2003-02-10 |
2009-06-20 |
Элан Фармасьютикалз, Инк. |
Композиции иммуноглобулина и способ их получения
|
|
JP4605798B2
(ja)
|
2003-03-10 |
2011-01-05 |
シェーリング コーポレイション |
Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
|
|
DK2335725T3
(en)
|
2003-04-04 |
2017-01-23 |
Genentech Inc |
Highly concentrated antibody and protein formulations
|
|
CN1816356A
(zh)
|
2003-05-14 |
2006-08-09 |
免疫原公司 |
药物缀合物组合物
|
|
EP1498123A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma S.A. |
Emulsifying systems containing azetidine derivatives
|
|
US20070212346A1
(en)
|
2003-10-09 |
2007-09-13 |
Tomoyuki Igawa |
Highly Concentrated Stabilized Igm Solution
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
AR046833A1
(es)
|
2003-11-10 |
2005-12-28 |
Schering Corp |
Anticuerpos anti-interleuquina-10
|
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
|
US20070184050A1
(en)
|
2003-12-25 |
2007-08-09 |
Kirin Beer Kabushiki Kaisha |
Stable water-based medicinal preparation containing antibody
|
|
PT2311873T
(pt)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
Anticorpo monoclonal específico para m-csf e respetivos usos
|
|
RU2390353C2
(ru)
|
2004-02-12 |
2010-05-27 |
Мерк Патент Гмбх |
Высококонцентрированные жидкие композиции анти-egfr антител
|
|
CN1942201B
(zh)
|
2004-02-17 |
2012-06-20 |
先灵公司 |
调节il-23活性的方法；相关试剂
|
|
EP1755659B1
(en)
|
2004-03-24 |
2011-11-02 |
Abbott Biotherapeutics Corp. |
Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
|
|
AU2005249360B2
(en)
|
2004-04-12 |
2011-07-21 |
Medimmune, Llc |
Anti-IL-9 antibody formulations and uses thereof
|
|
US20110142858A1
(en)
|
2004-06-07 |
2011-06-16 |
Ramot At Tel Aviv University Ltd. |
Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
SG190665A1
(en)
|
2004-07-30 |
2013-06-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
AU2006207901A1
(en)
|
2005-01-28 |
2006-08-03 |
Wyeth |
Stabilized liquid polypeptide formulations
|
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
KR100996801B1
(ko)
|
2005-03-08 |
2010-11-25 |
파마시아 앤드 업존 캄파니 엘엘씨 |
항-ＭＡｄＣＡＭ 항체 조성물
|
|
CN101166763B
(zh)
|
2005-04-18 |
2012-09-19 |
伊达研究和发展有限公司 |
稳定的抗乙肝病毒(hbv)抗体配制剂
|
|
PL1874818T3
(pl)
|
2005-04-22 |
2011-09-30 |
Lilly Co Eli |
Przeciwciała swoiste wobec TGF-beta 1
|
|
EP2418278A3
(en)
|
2005-05-09 |
2012-07-04 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
EP2390267B1
(en)
|
2005-06-07 |
2013-06-05 |
ESBATech - a Novartis Company LLC |
Stable and soluble antibodies inhibiting TNF(alpha)
|
|
KR20080019249A
(ko)
|
2005-06-15 |
2008-03-03 |
쉐링 코포레이션 |
안정한 항체 제형
|
|
ES2410406T3
(es)
|
2005-06-30 |
2013-07-01 |
Janssen Biotech, Inc. |
Anticuerpos anti-IL-23, composiciones, procedimientos y usos
|
|
EP1909838A2
(en)
|
2005-07-29 |
2008-04-16 |
Amgen Inc. |
Formulations that inhibit protein aggregation
|
|
BRPI0614100A2
(pt)
|
2005-08-03 |
2011-03-09 |
Immunogen Inc |
formulações de imunoconjugado lìquidas
|
|
EP1937721B1
(en)
|
2005-08-25 |
2010-07-28 |
Eli Lilly And Company |
Anti-il-23 antibodies
|
|
HUE032131T2
(en)
|
2005-08-31 |
2017-09-28 |
Merck Sharp & Dohme |
Constructed anti-IL-23 antibodies
|
|
AU2006291005A1
(en)
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-CD3 antibody formulations
|
|
WO2007036745A2
(en)
|
2005-09-30 |
2007-04-05 |
Medimmune Limited |
Interleukin-13 antibody composition
|
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
|
EP3219328B1
(en)
|
2005-12-29 |
2020-06-17 |
Janssen Biotech, Inc. |
Human anti-il-23 antibodies, compositions, method and uses
|
|
US20080071063A1
(en)
|
2006-02-03 |
2008-03-20 |
Medimmune, Inc. |
Protein Formulations
|
|
AU2007229554A1
(en)
|
2006-03-28 |
2007-10-04 |
F. Hoffmann-La Roche Ag |
Anti-IGF-1R human monoclonal antibody formulation
|
|
MX2008013535A
(es)
|
2006-04-21 |
2008-10-29 |
Amgen Inc |
Agentes amortiguadores para formulaciones biofarmaceuticas.
|
|
CN101426817B
(zh)
|
2006-04-21 |
2013-07-10 |
诺华有限公司 |
拮抗性抗-cd40抗体药物组合物
|
|
AU2007260787A1
(en)
|
2006-06-13 |
2007-12-21 |
Zymogenetics, Inc |
IL-17 and IL-23 antagonists and methods of using the same
|
|
US20080112953A1
(en)
|
2006-10-06 |
2008-05-15 |
Amgen Inc. |
Stable formulations
|
|
WO2008051363A2
(en)
|
2006-10-20 |
2008-05-02 |
Amgen Inc. |
Stable polypeptide formulations
|
|
US8034906B2
(en)
|
2006-10-27 |
2011-10-11 |
Abbott Biotechnology Ltd. |
Crystalline anti-hTNFalpha antibodies
|
|
JP5410985B2
(ja)
|
2006-12-05 |
2014-02-05 |
クルセル ホランド ベー ヴェー |
液体抗狂犬病抗体製剤
|
|
EP2628752A1
(en)
|
2006-12-14 |
2013-08-21 |
Merck Sharp & Dohme Corp. |
Engineered anti-TSLP antibody
|
|
JP5577098B2
(ja)
|
2006-12-21 |
2014-08-20 |
アムジエン・インコーポレーテツド |
ポリペプチドを含有する安定な緩衝化された製剤
|
|
CL2008000058A1
(es)
|
2007-01-09 |
2008-05-23 |
Wyeth Corp |
Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
|
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Ｉｌ-２３拮抗劑於治療感染之用途
|
|
US20100055111A1
(en)
|
2007-02-14 |
2010-03-04 |
Med. College Of Georgia Research Institute, Inc. |
Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
|
|
ATE554791T1
(de)
|
2007-02-23 |
2012-05-15 |
Schering Corp |
Gentechnisch hergestellte anti-il-23p19- antikörper
|
|
EP2064242A1
(en)
|
2007-02-23 |
2009-06-03 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
|
RU2476442C2
(ru)
|
2007-03-29 |
2013-02-27 |
Эббот Лэборетриз |
Кристаллические антитела против il-12 человека
|
|
WO2008121615A2
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Inc. |
Antibody formulation
|
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
BRPI0814252B8
(pt)
|
2007-06-14 |
2021-05-25 |
Biogen Idec Inc |
composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
|
|
EP2535354B1
(en)
|
2007-06-18 |
2017-01-11 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
|
US7951368B2
(en)
|
2007-06-25 |
2011-05-31 |
Amgen Inc. |
Compositions of specific binding agents to hepatocyte growth factor
|
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
US20100286038A1
(en)
|
2007-09-21 |
2010-11-11 |
Valentyn Antochshuk |
Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
|
|
EP2205276A4
(en)
|
2007-09-28 |
2012-08-15 |
Janssen Biotech Inc |
ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
|
|
AR068723A1
(es)
|
2007-10-05 |
2009-12-02 |
Glaxo Group Ltd |
Proteina que se une a antigenos que se une a il-23 humana y sus usos
|
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
NZ585516A
(en)
|
2007-12-21 |
2012-07-27 |
Hoffmann La Roche |
Anti-cd20 antibody formulation
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
JP2011507922A
(ja)
|
2007-12-28 |
2011-03-10 |
バイオインヴェント インターナショナル アーベー |
配合物
|
|
CN102202643A
(zh)
|
2008-02-07 |
2011-09-28 |
安姆根有限公司 |
稳定化的蛋白组合物
|
|
CN104548091A
(zh)
|
2008-02-11 |
2015-04-29 |
治疗科技公司 |
用于肿瘤治疗的单克隆抗体
|
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
|
EP3605088A1
(en)
|
2008-04-09 |
2020-02-05 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
NZ589434A
(en)
|
2008-06-03 |
2012-11-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2010001617A1
(en)
|
2008-07-04 |
2010-01-07 |
Ono Pharmaceutical Co., Ltd. |
Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
|
|
WO2010027766A1
(en)
|
2008-08-27 |
2010-03-11 |
Schering Corporation |
Lyophilized formulatons of engineered anti-il-23p19 antibodies
|
|
TR201802935T4
(tr)
|
2008-09-19 |
2018-03-21 |
Pfizer |
Stabil sıvı antikor formülasyonu.
|
|
CA2738243C
(en)
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
|
WO2010062372A2
(en)
|
2008-11-03 |
2010-06-03 |
President And Fellows Of Harvard College |
Methods for modulating nf-kb using gibberellins
|
|
PE20120204A1
(es)
|
2008-11-17 |
2012-03-03 |
Genentech Inc |
Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
|
|
WO2010069858A1
(en)
|
2008-12-19 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition
|
|
AU2010221156A1
(en)
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
|
JP2012519712A
(ja)
*
|
2009-03-06 |
2012-08-30 |
メディミューン，エルエルシー |
ヒト化抗ｃｄ１９抗体製剤
|
|
EP2230312A1
(en)
|
2009-03-19 |
2010-09-22 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Probe compound for detecting and isolating enzymes and means and methods using the same
|
|
CA2760185A1
(en)
|
2009-05-04 |
2010-11-11 |
Abbott Biotechnology Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha antibodies
|
|
US9155745B2
(en)
|
2009-06-16 |
2015-10-13 |
Universite De Geneve |
Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
|
|
CA2765220A1
(en)
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
|
US20120121580A1
(en)
|
2009-07-28 |
2012-05-17 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
WO2011024862A1
(ja)
|
2009-08-31 |
2011-03-03 |
三洋化成工業株式会社 |
タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及び液体洗剤組成物、並びに、この安定化剤を用いるタンパク質の安定化方法
|
|
CN102574924A
(zh)
|
2009-09-03 |
2012-07-11 |
先灵公司 |
抗-gitr抗体
|
|
US20110059079A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody Coformulations
|
|
BR112012005869A2
(pt)
|
2009-09-15 |
2017-01-31 |
Althea Tech Inc |
cristais da proteína a, cristais reticulados e métodos de utilização dos mesmos
|
|
NZ599761A
(en)
|
2009-11-04 |
2014-04-30 |
Merck Sharp & Dohme |
Engineered anti-tslp antibody
|
|
PL2515941T3
(pl)
|
2009-12-21 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Preparat farmaceutyczny zawierający bewacyzumab
|
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
|
US8318807B2
(en)
|
2010-02-03 |
2012-11-27 |
Laurus Labs Private Limited |
Pterostilbene cocrystals
|
|
NZ602054A
(en)
|
2010-03-17 |
2014-10-31 |
Abbott Res Bv |
Anti-nerve growth factor (ngf) antibody compositions
|
|
WO2011139718A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
|
EP2590971A4
(en)
|
2010-06-17 |
2014-12-10 |
Fuzians Biomedicals Inc |
COMPOUNDS SUITABLE FOR ANTIVIRAL ACTIVE SUBSTANCES, COMPOSITIONS AND METHOD OF USE THEREOF
|
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
|
FR2962908A1
(fr)
|
2010-07-20 |
2012-01-27 |
Lfb Biotechnologies |
Formulation d'anticorps anti-cd20
|
|
WO2012018538A2
(en)
|
2010-07-26 |
2012-02-09 |
Schering Corporation |
Bioassays for determining pd-1 modulation
|
|
JP5918246B2
(ja)
|
2010-10-06 |
2016-05-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
|
|
AU2012236962B2
(en)
|
2011-03-25 |
2017-05-11 |
Amgen Inc. |
Anti-sclerostin antibody crystals and formulations thereof
|
|
KR102031020B1
(ko)
|
2011-03-31 |
2019-10-14 |
머크 샤프 앤드 돔 코포레이션 |
인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
|
|
EA201391489A1
(ru)
|
2011-04-07 |
2014-02-28 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Композиции со сниженной вязкостью
|
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
|
WO2013012022A1
(ja)
|
2011-07-19 |
2013-01-24 |
中外製薬株式会社 |
アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
|
|
PE20181541A1
(es)
|
2011-10-27 |
2018-09-26 |
Massachusetts Inst Technology |
Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
|
|
NZ627859A
(en)
|
2012-01-23 |
2015-09-25 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
|
KR101730694B1
(ko)
|
2012-03-07 |
2017-04-27 |
카딜라 핼쓰캐어 리미티드 |
TNF-α 항체의 약제학적 제형
|
|
US9637740B2
(en)
|
2012-04-02 |
2017-05-02 |
President And Fellows Of Harvard College |
Cancer treatment and immune system regulation through FAT10 pathway inhibition
|
|
WO2013165791A1
(en)
|
2012-05-03 |
2013-11-07 |
Boehringer Ingelheim International Gmbh |
Anti-il-23p19 antibodies
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
WO2014004436A2
(en)
|
2012-06-27 |
2014-01-03 |
Merck Sharp & Dohme Corp. |
Crystalline anti-human il-23 antibodies
|
|
AU2013285422B2
(en)
|
2012-07-04 |
2017-04-27 |
F. Hoffmann-La Roche Ag |
Covalently linked antigen-antibody conjugates
|
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
|
US20140227250A1
(en)
|
2012-08-23 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to tslp
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
US9649383B2
(en)
|
2012-11-19 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Liquid formulations for TNFR:Fc fusion proteins
|
|
US20150307606A1
(en)
|
2012-12-13 |
2015-10-29 |
Ashwin Basarkar |
Lyophilized spherical pellets of anti-il-23 antibodies
|
|
US9700633B2
(en)
|
2013-01-28 |
2017-07-11 |
Jenkem Technology Co., Ltd., Tianjin Branch |
Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
|
|
KR102274714B1
(ko)
*
|
2013-03-13 |
2021-07-09 |
씨젠 인크. |
사이클로덱스트린 및 항체-약물 포합체 제형
|
|
WO2014193898A1
(en)
*
|
2013-05-31 |
2014-12-04 |
Merck Sharp & Dohme Corp. |
Combination therapies for cancer
|
|
RU2702108C2
(ru)
|
2013-07-16 |
2019-10-04 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
|
|
ES2687094T3
(es)
|
2013-07-23 |
2018-10-23 |
Novaliq Gmbh |
Composiciones estabilizadas de anticuerpos
|
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
EP3508502B1
(en)
|
2013-09-20 |
2023-04-26 |
Bristol-Myers Squibb Company |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
|
US9782470B2
(en)
|
2013-10-16 |
2017-10-10 |
Merck Sharp & Dohme Corp. |
Method of obtaining thermostable dried vaccine formulations
|
|
EP3119913B1
(en)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
|
RU2589691C2
(ru)
|
2014-06-16 |
2016-07-10 |
Общество с ограниченной ответственностью "Промоген-МАТ" |
Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
|
|
WO2015196091A1
(en)
|
2014-06-20 |
2015-12-23 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
|
MA40344A
(fr)
*
|
2014-07-18 |
2016-01-21 |
Advaxis Inc |
Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
US20170239351A1
(en)
|
2014-08-11 |
2017-08-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
US20160355589A1
(en)
|
2014-08-19 |
2016-12-08 |
Merck Sharp & Dohme Corp. |
Anti-tigit antibodies
|
|
JP6827415B2
(ja)
|
2014-10-31 |
2021-02-10 |
メレオ バイオファーマ ５ インコーポレイテッド |
疾患の処置のための併用療法
|
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
US20170360929A1
(en)
|
2014-12-23 |
2017-12-21 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
|
CA2971757A1
(en)
|
2015-01-20 |
2016-07-28 |
Immunexcite, Inc. |
Compositions and methods for cancer immunotherapy
|
|
MX374853B
(es)
|
2015-02-19 |
2025-03-06 |
Compugen Ltd |
Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso.
|
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
EP3277716B1
(en)
*
|
2015-04-03 |
2020-06-24 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
KR20250004095A
(ko)
*
|
2015-04-17 |
2025-01-07 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
|
|
WO2016176504A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
WO2017009813A1
(en)
|
2015-07-16 |
2017-01-19 |
Laurus Labs Private Limited |
Novel caffeine cocrystals and their polymorphic forms
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
JP6976241B2
(ja)
|
2015-08-14 |
2021-12-08 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗ｔｉｇｉｔ抗体
|
|
BR112018004069A2
(pt)
|
2015-09-01 |
2021-07-13 |
First Wave Bio, Inc. |
composição farmacêutica sólida, preparação de enema compreendendo niclosamida, formulação de enema, uso de niclosamida e kit
|
|
IL257798B2
(en)
|
2015-09-02 |
2024-10-01 |
Immutep Sas |
Antibodies against LAG-3
|
|
US20180251548A1
(en)
|
2015-09-14 |
2018-09-06 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
|
|
MY186016A
(en)
|
2015-09-25 |
2021-06-14 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
US20170097333A1
(en)
|
2015-09-28 |
2017-04-06 |
Merck Sharp & Dohme Corp. |
Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
|
|
RU2731418C2
(ru)
*
|
2015-09-28 |
2020-09-02 |
Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. |
Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
|
|
SG10201912736UA
(en)
|
2015-10-01 |
2020-02-27 |
Potenza Therapeutics Inc |
Anti-tigit antigen-binding proteins and methods of use thereof
|
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
|
US11173214B2
(en)
|
2015-11-25 |
2021-11-16 |
Legochem Biosciences, Inc. |
Antibody-drug conjugates comprising branched linkers and methods related thereto
|
|
US20190010224A1
(en)
|
2015-12-22 |
2019-01-10 |
Merck Sharp & Dohme Corp. |
Formulations of engineered anti-il-10 antibodies
|
|
US10221242B2
(en)
|
2016-01-21 |
2019-03-05 |
Pfizer Inc. |
Antibodies specific for epidermal growth factor receptor variant III and their uses
|
|
MX393609B
(es)
|
2016-05-18 |
2025-03-24 |
Boehringer Ingelheim Int |
Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer
|
|
FI3468586T3
(fi)
|
2016-06-14 |
2024-10-29 |
Xencor Inc |
Bispesifisiä immuuniaktivaatiota vapauttavia vasta-aineita
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CA3040504A1
(en)
|
2016-10-14 |
2018-04-19 |
Xencor, Inc. |
Il15/il15ra heterodimeric fc-fusion proteins
|
|
US20190374639A1
(en)
|
2016-11-21 |
2019-12-12 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
CN112057419B
(zh)
|
2017-03-01 |
2023-08-22 |
免疫医疗有限公司 |
单克隆抗体的配制品
|
|
TW202228779A
(zh)
|
2017-03-01 |
2022-08-01 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
WO2018204374A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
UA129862C2
(uk)
|
2017-05-02 |
2025-08-27 |
Мерк Шарп Енд Доум Елелсі |
Склад для лікування злоякісної пухлини або хронічної інфекції
|
|
RU2020112302A
(ru)
|
2017-09-05 |
2021-10-06 |
Мерк Шарп И Доум Корп. |
Соединения для уменьшения вязкости биологических композиций
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|